TENAX THERAPEUTICS, INC.

TENAX THERAPEUTICS, INC. (TENX) is a US-listed equity tracked across major market indices. Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

The company reports trailing twelve-month revenue of $0 and net loss of $15.72M. Key metrics include a return on equity of -13.7%, a debt-to-equity ratio of 0.07.

FINOTAUR provides free research summaries, news aggregation, and fundamentals for TENX to support both active traders and long-term investors.